Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: An exploratory analysis
Bibliographic record
Abstract
7135 Background: For NSCLC pts with good performance status, second-line treatment with chemotherapy improves survival. Routine administration of second-line chemotherapy has increased the percentage of pts receiving third-line therapy. In a recent multicenter, randomized, phase III comparison of pemetrexed versus docetaxel in previously treated pts with advanced NSCLC, survival time with pemetrexed therapy was similar to docetaxel (median 8.3 vs 7.9 months). Over 40% of pts in the study received third-line chemotherapy post study. Of those pts treated with pemetrexed, 32% received docetaxel post study. The aim of this exploratory analysis was to evaluate if the survival observed in the pemetrexed arm was due to a cross-over effect of post study chemotherapy with docetaxel as opposed to other post study chemotherapy agents. Methods: Survival analyses were performed using Kaplan-Meier method in 3 subsets of patients with respect to their post study treatment. Results: In total, 541 pts received either pemetrexed or docetaxel; 48% of pts in the pemetrexed arm and 39% of pts in the docetaxel arm received third line chemotherapy. In the pemetrexed arm, the median survival of pts who received post study docetaxel was 1 month less (9.6) than the median survival of pts who received other post study chemotherapy agents (10.6; p=.219). Conclusions: In the original study, overall survival was similar for both treatment arms. In this evaluation, these results provide no evidence that the overall survival observed in the pemetrexed arm with third-line post study docetaxel is different than that observed in the pts who received other third-line post study chemotherapy agents. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly & Co. Aventis; Eli Lilly & Co. Eli Lilly & Co. Eli Lilly & Co. Eli Lilly & Co.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.006 | 0.006 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.005 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".